Hematological abnormalities in neonatal patients treated with extracorporeal membrane oxygenation (ECMO)

Douglas P. Zavadil, Alfred H. Stammers, Lynne D Willett, Joseph J. Deptula, Kevin A. Christensen, R. Troy Sydzyik

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The physical process of extracorporeal membrane oxygenation (ECMO) results in derangement of the hemostatic mechanism, which may lead to increased morbidity, secondary to the disease process. The purpose of this study was to evaluate the hematological status of neonates undergoing ECMO therapy, and to evaluate coagulation tests in predicting hemorrhagic risk. Following Institutional Review Board approval, 30 patients undergoing ECMO treatment were retrospectively entered into this study. Medical records were reviewed and indicators of hemostasis, transfusion, morbidity, and outcomes recorded. Assessment of coagulation was determined through serial analysis of platelet count, fibrinogen concentration, prothrombin time (PT), activated partial thromboplastin time (aPTT), antithrombin III, fibrin split products, D-dimers, plasma free hemoglobin, activated clotting time, ionized calcium, and thrombelastography (TEG). Median total transfusion requirements for all patients were 1.79 ml/kg/ECMO hr. Fifty-seven percent of the 30 patients were diagnosed as coagulopathic according to Extracorporeal Life Support Organization standards. Patients were separated into either a hemorrhagic group (HEM, >2.0 ml/kg/ECMO hr, n=13) or a nonhemorrhagic group (N-HEM, n=17), with HEM patients requiting twice the transfusion volume of N-HEM (p<0.0001). Hemorrhagic complications were reported in 53.8% of the HEM patients vs. 35.3% in the N-HEM group. HEM patients were transfused with significantly greater quantities of platelets on days 1,3,5, and 8 and packed red blood cells on day 7 when compared to N-HEM (p<0.05). TEG determination showed significant differences between groups on days 3 and 6 (p<0.005), and 8 (p<0.05). Derangements in hemostasis resulting from ECMO are profound, with methods of assessing coagulation complicated by both the variability in patient condition and lack of specificity of laboratory tests. Interpretation of TEG data has shown to be a valuable supplement for managing this challenging patient population.

Original languageEnglish (US)
Pages (from-to)83-90
Number of pages8
JournalJournal of Extra-Corporeal Technology
Volume30
Issue number2
StatePublished - Jun 1 1998

Fingerprint

Extracorporeal Membrane Oxygenation
Thrombelastography
Hemostasis
Physical Phenomena
Morbidity
Antithrombin III
Partial Thromboplastin Time
Research Ethics Committees
Prothrombin Time
Hemostatics
Fibrin
Platelet Count
Fibrinogen
Medical Records
Hemoglobins
Blood Platelets
Erythrocytes
Organizations
Newborn Infant
Calcium

Keywords

  • Extracorporeal membrane oxygenation (ECMO)
  • Respiratory failure
  • Thrombelastograph

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Zavadil, D. P., Stammers, A. H., Willett, L. D., Deptula, J. J., Christensen, K. A., & Sydzyik, R. T. (1998). Hematological abnormalities in neonatal patients treated with extracorporeal membrane oxygenation (ECMO). Journal of Extra-Corporeal Technology, 30(2), 83-90.

Hematological abnormalities in neonatal patients treated with extracorporeal membrane oxygenation (ECMO). / Zavadil, Douglas P.; Stammers, Alfred H.; Willett, Lynne D; Deptula, Joseph J.; Christensen, Kevin A.; Sydzyik, R. Troy.

In: Journal of Extra-Corporeal Technology, Vol. 30, No. 2, 01.06.1998, p. 83-90.

Research output: Contribution to journalArticle

Zavadil, DP, Stammers, AH, Willett, LD, Deptula, JJ, Christensen, KA & Sydzyik, RT 1998, 'Hematological abnormalities in neonatal patients treated with extracorporeal membrane oxygenation (ECMO)', Journal of Extra-Corporeal Technology, vol. 30, no. 2, pp. 83-90.
Zavadil, Douglas P. ; Stammers, Alfred H. ; Willett, Lynne D ; Deptula, Joseph J. ; Christensen, Kevin A. ; Sydzyik, R. Troy. / Hematological abnormalities in neonatal patients treated with extracorporeal membrane oxygenation (ECMO). In: Journal of Extra-Corporeal Technology. 1998 ; Vol. 30, No. 2. pp. 83-90.
@article{6679328c3e054ea5927cd72f18784284,
title = "Hematological abnormalities in neonatal patients treated with extracorporeal membrane oxygenation (ECMO)",
abstract = "The physical process of extracorporeal membrane oxygenation (ECMO) results in derangement of the hemostatic mechanism, which may lead to increased morbidity, secondary to the disease process. The purpose of this study was to evaluate the hematological status of neonates undergoing ECMO therapy, and to evaluate coagulation tests in predicting hemorrhagic risk. Following Institutional Review Board approval, 30 patients undergoing ECMO treatment were retrospectively entered into this study. Medical records were reviewed and indicators of hemostasis, transfusion, morbidity, and outcomes recorded. Assessment of coagulation was determined through serial analysis of platelet count, fibrinogen concentration, prothrombin time (PT), activated partial thromboplastin time (aPTT), antithrombin III, fibrin split products, D-dimers, plasma free hemoglobin, activated clotting time, ionized calcium, and thrombelastography (TEG). Median total transfusion requirements for all patients were 1.79 ml/kg/ECMO hr. Fifty-seven percent of the 30 patients were diagnosed as coagulopathic according to Extracorporeal Life Support Organization standards. Patients were separated into either a hemorrhagic group (HEM, >2.0 ml/kg/ECMO hr, n=13) or a nonhemorrhagic group (N-HEM, n=17), with HEM patients requiting twice the transfusion volume of N-HEM (p<0.0001). Hemorrhagic complications were reported in 53.8{\%} of the HEM patients vs. 35.3{\%} in the N-HEM group. HEM patients were transfused with significantly greater quantities of platelets on days 1,3,5, and 8 and packed red blood cells on day 7 when compared to N-HEM (p<0.05). TEG determination showed significant differences between groups on days 3 and 6 (p<0.005), and 8 (p<0.05). Derangements in hemostasis resulting from ECMO are profound, with methods of assessing coagulation complicated by both the variability in patient condition and lack of specificity of laboratory tests. Interpretation of TEG data has shown to be a valuable supplement for managing this challenging patient population.",
keywords = "Extracorporeal membrane oxygenation (ECMO), Respiratory failure, Thrombelastograph",
author = "Zavadil, {Douglas P.} and Stammers, {Alfred H.} and Willett, {Lynne D} and Deptula, {Joseph J.} and Christensen, {Kevin A.} and Sydzyik, {R. Troy}",
year = "1998",
month = "6",
day = "1",
language = "English (US)",
volume = "30",
pages = "83--90",
journal = "Journal of Extra-Corporeal Technology",
issn = "0022-1058",
publisher = "American Society of Extra-Corporeal Technology",
number = "2",

}

TY - JOUR

T1 - Hematological abnormalities in neonatal patients treated with extracorporeal membrane oxygenation (ECMO)

AU - Zavadil, Douglas P.

AU - Stammers, Alfred H.

AU - Willett, Lynne D

AU - Deptula, Joseph J.

AU - Christensen, Kevin A.

AU - Sydzyik, R. Troy

PY - 1998/6/1

Y1 - 1998/6/1

N2 - The physical process of extracorporeal membrane oxygenation (ECMO) results in derangement of the hemostatic mechanism, which may lead to increased morbidity, secondary to the disease process. The purpose of this study was to evaluate the hematological status of neonates undergoing ECMO therapy, and to evaluate coagulation tests in predicting hemorrhagic risk. Following Institutional Review Board approval, 30 patients undergoing ECMO treatment were retrospectively entered into this study. Medical records were reviewed and indicators of hemostasis, transfusion, morbidity, and outcomes recorded. Assessment of coagulation was determined through serial analysis of platelet count, fibrinogen concentration, prothrombin time (PT), activated partial thromboplastin time (aPTT), antithrombin III, fibrin split products, D-dimers, plasma free hemoglobin, activated clotting time, ionized calcium, and thrombelastography (TEG). Median total transfusion requirements for all patients were 1.79 ml/kg/ECMO hr. Fifty-seven percent of the 30 patients were diagnosed as coagulopathic according to Extracorporeal Life Support Organization standards. Patients were separated into either a hemorrhagic group (HEM, >2.0 ml/kg/ECMO hr, n=13) or a nonhemorrhagic group (N-HEM, n=17), with HEM patients requiting twice the transfusion volume of N-HEM (p<0.0001). Hemorrhagic complications were reported in 53.8% of the HEM patients vs. 35.3% in the N-HEM group. HEM patients were transfused with significantly greater quantities of platelets on days 1,3,5, and 8 and packed red blood cells on day 7 when compared to N-HEM (p<0.05). TEG determination showed significant differences between groups on days 3 and 6 (p<0.005), and 8 (p<0.05). Derangements in hemostasis resulting from ECMO are profound, with methods of assessing coagulation complicated by both the variability in patient condition and lack of specificity of laboratory tests. Interpretation of TEG data has shown to be a valuable supplement for managing this challenging patient population.

AB - The physical process of extracorporeal membrane oxygenation (ECMO) results in derangement of the hemostatic mechanism, which may lead to increased morbidity, secondary to the disease process. The purpose of this study was to evaluate the hematological status of neonates undergoing ECMO therapy, and to evaluate coagulation tests in predicting hemorrhagic risk. Following Institutional Review Board approval, 30 patients undergoing ECMO treatment were retrospectively entered into this study. Medical records were reviewed and indicators of hemostasis, transfusion, morbidity, and outcomes recorded. Assessment of coagulation was determined through serial analysis of platelet count, fibrinogen concentration, prothrombin time (PT), activated partial thromboplastin time (aPTT), antithrombin III, fibrin split products, D-dimers, plasma free hemoglobin, activated clotting time, ionized calcium, and thrombelastography (TEG). Median total transfusion requirements for all patients were 1.79 ml/kg/ECMO hr. Fifty-seven percent of the 30 patients were diagnosed as coagulopathic according to Extracorporeal Life Support Organization standards. Patients were separated into either a hemorrhagic group (HEM, >2.0 ml/kg/ECMO hr, n=13) or a nonhemorrhagic group (N-HEM, n=17), with HEM patients requiting twice the transfusion volume of N-HEM (p<0.0001). Hemorrhagic complications were reported in 53.8% of the HEM patients vs. 35.3% in the N-HEM group. HEM patients were transfused with significantly greater quantities of platelets on days 1,3,5, and 8 and packed red blood cells on day 7 when compared to N-HEM (p<0.05). TEG determination showed significant differences between groups on days 3 and 6 (p<0.005), and 8 (p<0.05). Derangements in hemostasis resulting from ECMO are profound, with methods of assessing coagulation complicated by both the variability in patient condition and lack of specificity of laboratory tests. Interpretation of TEG data has shown to be a valuable supplement for managing this challenging patient population.

KW - Extracorporeal membrane oxygenation (ECMO)

KW - Respiratory failure

KW - Thrombelastograph

UR - http://www.scopus.com/inward/record.url?scp=0031870112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031870112&partnerID=8YFLogxK

M3 - Article

C2 - 10182118

AN - SCOPUS:0031870112

VL - 30

SP - 83

EP - 90

JO - Journal of Extra-Corporeal Technology

JF - Journal of Extra-Corporeal Technology

SN - 0022-1058

IS - 2

ER -